Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2006

View Archived Issues

PowderMed's vaccine approach achieves crossprotection for influenza and drifting strains

Nuvo Research acquires fqubed

IDM Pharma completes sale of non-core assets to Pharmexa

Closing of Pain Therapeutics and King's strategic alliance

pSivida completes acquisition of Control Delivery Systems

MAA completed for Genasense plus chemotherapy in malignant melanoma

InterMune completes sale of Infergen to Valeant

Amarin licenses LAX-202 rights for MS fatigue to Multicell Technologies

Anturol completes phase II dose-ranging study

U.S. Navy to receive defense appropriation for Hemopure R&D

Inex shareholders to vote on Targeted Immunotherapy spin-out

FDA clears NT-proBNP test for new risk stratification use

New quinolone antibacterials emerge from Pfizer R&D

sanofi-aventis prepares and tests new histamine H3 receptor antagonists

Preclinical and clinical erythropoietic activity of CNTO-528

Method for diagnosis/prognosis of wound infection claimed in Ethicon patent

Albaconazole superior to fluconazole in phase II vulvovaginal candidiasis trial

New data support Factor Xa inhibition for thromboprophylaxis

Tamoxifen efficacy in breast cancer affected by CYP450 2D6 genotype

Novel HIV integrase inhibitors designed by Bioflexis

Immunosuppressive effects of NK-026680 useful for acute GVHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...